Alpha₁ blockers

References

• The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988: 148(5): 1023–38
   PubMedGoogle Scholar
• Kaplan NM. Maximally reducing cardiovascular risk in the treatment of hypertension. Ann Intern Med 1988: 109(Jul 1): 36–40
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Evolution of the clinical management of hypertension: emerging role of “specific” vasodilators as initial therapy. Am J Med 1987: 82(Suppl 1A): 36–43
   PubMed Web of Science ®Google Scholar
• Ahlquist RP. Study of the adrenotropic receptors. Am J Physiol 1948: 153(Jun): 586–600
   PubMedGoogle Scholar
• Lefkowitz RJ. Pharmacologic principles related to the autonomic nervous system. In: Wyngaarden JB, Smith LH Jr, eds. Cecil textbook of medicine. 18th ed. Philadelphia: WB Saunders, 1988: 133–40
   Google Scholar
• Langer SZ, Hicks PE. Alpha-adrenoreceptor subtypes in blood vessels: physiology and pharmacology. J Cardiovasc Pharmacol 1984: 6(Suppl 4): S547–58
   PubMed Web of Science ®Google Scholar
• Colucci WS. New developments in alpha-adrenergic receptor pharmacology: implications for the initial treatment of hypertension. Am J Cardiol 1983: 51(4): 639–43
   PubMed Web of Science ®Google Scholar
• Weiner N. Norepinephrine, epinephrine, and the sympathomimetic amines. In: Gilman A, Goodman LS, Rail TW, et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 145–80
   Google Scholar
• Luther RR. New perspectives on selective alpha1 blockade. Am J Hypertens 1989: 2(9): 729–35
   PubMed Web of Science ®Google Scholar
• Shionoiri H, Yasuda G, Yoshimura H, et al. Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987: 10(1): 90–5
   PubMed Web of Science ®Google Scholar
• Titmarsh S, Monk JP. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 1987: 33(5): 461–77
   PubMed Web of Science ®Google Scholar
• Elliott HL, Meredith PA, Vincent J, et al. Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986: 21(Suppl 1): 27–31S
   PubMedGoogle Scholar
• Brogden RN, Heel RC, Speight TM, et al. Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 1977: 14(3): 163–97
   PubMed Web of Science ®Google Scholar
• Frishman WH, Charlap S. Alpha-adrenergic blockers. Med Clin North Am 1988: 72(2): 427–40
   PubMed Web of Science ®Google Scholar
• Strom J, Frishman W, Wexler J, et al. The acute hemodynamic effects of terazosin. (Abstr) Clin Pharmacol Ther 1989: 45(2): 167
   Web of Science ®Google Scholar
• Colucci WS. Alpha-adrenergic receptor blockade with prazosin: consideration of hypertension, heart failure, and potential new applications. Ann Intern Med 1982: 97(1): 67–77
   PubMed Web of Science ®Google Scholar
• Jungers P, Ganeval D, Pertuiset N, et al. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. Am J Med 1986: 80(Suppl 5B): 94–9
   PubMed Web of Science ®Google Scholar
• Preston RA, O'Connor DT, Stone RA. Prazosin and renal hemodynamics: arteriolar vasodilation during therapy of essential hypertension in man. J Cardiovasc Pharmacol 1979: 1(3): 277–86
   PubMed Web of Science ®Google Scholar
• O'Connor DT, Preston RA, Sasso EH. Renal perfusion changes during treatment of essential hypertension: prazosin versus propranolol. J Cardiovasc Pharmacol 1979: 1(6 Suppl): S38–42
   PubMed Web of Science ®Google Scholar
• Weber MA. Sympathetic nervous system and hypertension: therapeutic perspectives. Am J Hypertens 1989: 2(3 Pt2): 147–52S
   Google Scholar
• Taylor SH. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction. Am Heart J 1988: 116(6 Pt 2): 1735–47
   PubMed Web of Science ®Google Scholar
• Chobanian AV. A symposium: beta blockade, cardioselectivity and intrinsic sympathomimetic activity. Am J Cardiol 1987: 59(13): 1–2F
   PubMed Web of Science ®Google Scholar
• Saunders E. Drug treatment considerations for the hypertensive black patient. J Fam Pract 1988: 26(6): 659–64
   PubMed Web of Science ®Google Scholar
• Pool JL. The role of alpha1-selective blockade in the management of hypertension. Proceedings of symposium on theoretical and clinical applications of alpha₁-receptor blockade. Carlsbad, CA: 1990 Feb: 30–40
   Google Scholar
• Torvik D, Madsbu HP. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension. Am J Cardiol 1987: 59(14): 68–72G
   Web of Science ®Google Scholar
• Luther RR, Glassman HN, Jordan DC, et al. Efficacy of terazosin as an antihypertensive agent. Am J Med 1986: 80(Suppl 5B): 73–6
   PubMed Web of Science ®Google Scholar
• Cox DA, Leader JP, Milson JA, et al. The antihypertensive effects of doxazosin: a clinical overview. Br J Clin Pharmacol 1986: 21(Suppl 1): 83–90S
   PubMedGoogle Scholar
• Hayduk K. Efficacy and safety of doxazosin in hypertension therapy. Am J Cardiol 1987: 59(14): 35–39G
   Web of Science ®Google Scholar
• Rudd P, Berenson G, Brown M, et al. Cumulative experience with terazosin administered in combination with diuretics. Am J Med 1986: 80(Suppl 5B): 49–54
   PubMed Web of Science ®Google Scholar
• Holtzman JL, Kaihlanen PM, Rider A, et al. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. Arch Intern Med 1988: 148(Mar): 539–43
   PubMedGoogle Scholar
• Luther RR, Glassman HN, Estep CB, et al. The effects of terazosin and methyclothiazide on blood pressure and serum lipids. Am Heart J 1989: 117(4): 842–7
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Black HR, Davidov M, et al. Experience with terazosin administered in combination with other antihypertensive agents. Am J Med 1986: 80(Suppl 5B): 55–61
   PubMed Web of Science ®Google Scholar
• Ott P, Storm TL, Krusell LR, et al. Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. Am J Cardiol 1987: 59(14): 73–77G
   Web of Science ®Google Scholar
• Nash DT, Schonfeld G, Reeves RL, et al. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. Am J Cardiol 1987: 59(14): 87–90G
   Web of Science ®Google Scholar
• Mazzola C, Guerrasio E. Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. Am Heart J 1988: 116(6 Pt 2): 1797–801
   PubMed Web of Science ®Google Scholar
• Lindner UK, von Manteuffel GE, Stafunsky M. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988: 116(Dec): 1814–19
   PubMed Web of Science ®Google Scholar
• Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988: 116(6 Pt 2): 1826–32
   PubMedGoogle Scholar
• Ruoff G, Cohen A, Hollifield JW, et al. Comparative trials of terazosin with other antihypertensive agents. Am J Med 1986: 80(Suppl 5B): 42–8
   PubMed Web of Science ®Google Scholar
• Mersey JH. Long-term experience with terazosin for treatment of mild to moderate hypertension. Am J Med 1986: 80(Suppl 5B): 68–72
   PubMed Web of Science ®Google Scholar
• Luther RR, Glassman HN, Estep CB, et al. Terazosin: a new selective alpha1-adrenergic blocking agent: results of long-term treatment in patients with essential hypertension. Am J Hypertens 1988: 1(3 Pt 3): 237–240S
   Google Scholar
• Tomoda F, Takata M, Yoshida K, et al. Hemodynamic and endocrinological effects of a new selective alpha1-blocking agent, terazosin, in patients with essential hypertension: results of long-term treatment. Am J Hypertens 1989: 2(11 Pt 1): 834–9
   PubMed Web of Science ®Google Scholar
• Grimm RH Jr. Alpha1-antagonists in the treatment of hypertension. Hypertension 1989: 13(5 Pt 2): 1–131–6
   PubMedGoogle Scholar
• Dauer AD, Abraham PA, Cohen A, et al. Terazosin: an effective once-daily monotherapy for the treatment of hypertension. Am J Med 1986: 80 (Suppl 5B): 29–34
   PubMed Web of Science ®Google Scholar
• Rosenthal J. A multicenter trial of doxazosin in West Germany. Am J Cardiol 1987: 59(14): 40–45G
   Web of Science ®Google Scholar
• Jackson EA. Issues with antihypertensive therapy: safety perspectives. Drug Intell Clin Pharm 1988: 22(Feb): 115–24
   PubMedGoogle Scholar
• Casale PN, Milner M, Devereux RB. Value of echocardiography left ventricular mass in predicting cardiovascular morbid events in hypertensive men. (Abstr) Circulation 1985: 72(Suppl III): 111–130
   Google Scholar
• Weber MA, Drayer JI, Baird WM. Echocardiographic evaluation of left ventricular hypertrophy. J Cardiovasc Pharmacol 1986: 8(Suppl 3): S61–8
   PubMed Web of Science ®Google Scholar
• McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987: 317(13): 787–92
   PubMed Web of Science ®Google Scholar
• Yasumoto K, Takata M, Kawakami H, et al. Regression of left ventricular hypertrophy and its mechanism in patients with essential hypertension treated with alpha1-blocking agent, terazosin. (Abstr) Japan Circ J 1986: 50(Aug): 772
   Google Scholar
• Leenen FH, Smith DL, Farkas RM, et al. Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans. Am J Med 1987: 82(May): 969–78
   PubMed Web of Science ®Google Scholar
• Schulman SP, Weiss JL, Becker LC, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990: 322(19): 1350–6
   PubMed Web of Science ®Google Scholar
• Liebson PR. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens 1990;3(6 Pt 1): 512–7 [erratum, Am J Hypertens 1990: 3(9): following Table of Contents]
   PubMed Web of Science ®Google Scholar
• Mulrow CD, Mulrow JP, Linn WD, et al. Relative efficacy of vasodilator therapy in chronic congestive heart failure: implications of randomized trials. JAMA 1988: 259(23): 3422–6
   PubMed Web of Science ®Google Scholar
• Cohn JN, Rector TS. Vasodilator therapy for heart failure: what have we learned from controlled clinical trials? (Editorial) JAMA 1988: 259(23): 3456–7
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986: 314(24): 1547–52
   PubMed Web of Science ®Google Scholar
• Deger G. Effect of terazosin on serum lipids. Am J Med 1986: 80(Suppl 5B): 82–5
   PubMed Web of Science ®Google Scholar
• Sperzel WD, Glassman HN, Jordan DC, et al. Overall safety of terazosin as an antihypertensive agent. Am J Med 1986: 80(Suppl 5B): 77–81
   PubMed Web of Science ®Google Scholar
• Grimm RH Jr, Hunninghake DB. Lipids and hypertension: implications of new guidelines for cholesterol management in the treatment of hypertension. Am J Med 1986: 80(Suppl 2A): 56–63
   PubMed Web of Science ®Google Scholar
• Roberts WC. Blood lipid levels and antihypertensive therapy. Drugs 1988: 36(Suppl 2): 33–40
   Google Scholar
• Amery A, Lijnen P. Alterations in lipid metabolism induced by antihypertensive therapy. Drugs 1988: 36(Suppl 2): 1–5
   PubMed Web of Science ®Google Scholar
• National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 1991: 114(3): 224–37
   PubMed Web of Science ®Google Scholar
• Ames R. Effects of diuretic drugs on the lipid profile. Drugs 1988: 36(Suppl 2): 33–40
   PubMed Web of Science ®Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes 1988: 37(Dec): 1595–607
   PubMedGoogle Scholar
• Fuller JH. Epidemiology of hypertension associated with diabetes mellitus. Hypertension 1985: 7(Suppl II): 11–3–7
   PubMedGoogle Scholar
• Pollare T, Lithell H, Selinus I, et al. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988: 31(7): 415–20
   PubMed Web of Science ®Google Scholar
• Swislocki AL, Hoffman BB, Sheu WH, et al. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989: 86(Suppl 1B): 14–8
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and Captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1988: 321(13): 868–73
   Web of Science ®Google Scholar
• Henderson WR, Shelhamer JH, Reingold DB, et al. Alpha-adrenergic hyper-responsiveness in asthma: analysis of vascular and pupillary responses. N Engl J Med 1979: 300(Mar 22): 642–7
   PubMed Web of Science ®Google Scholar
• Shiner RJ, Molho MI. Comparison between an alpha-adrenergic antagonist and β2-adrenergic agonist in bronchial asthma. Chest 1983: 83(4): 602–6
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Wilson NM, Vickers H. Prazosin, an alpha1-adrenoceptor antagonist, partially inhibits exercise-induced asthma. J Allergy Clin Immunol 1981: 68(6): 411–5
   PubMed Web of Science ®Google Scholar
• Walsh PC. Diseases of the prostate. In: Wyngaarden, Smith, eds,5 pp 1421–5
   Google Scholar
• Kirby RS, Coppinger SW, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987: 60(2): 136–42
   PubMedGoogle Scholar
• Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975: 47(2): 193–202
   PubMedGoogle Scholar
• Gerstenberg T, Blaabjerg J, Nielsen ML, et al. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia: a urodynamic investigation. Invest Urol 1980: 18(1): 29–31
   PubMedGoogle Scholar
• Caine M, Perlberg S, Shapiro A. Phenoxybenzamine for benign prostatic obstruction: review of 200 cases. Urology 1981: 17(6): 542–6
   PubMed Web of Science ®Google Scholar
• Lepor H, Knapp-Maloney G, Wozniak-Petrofsky J. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. Int J Clin Pharmacol Ther Toxicol 1989: 27(8): 392–7
   PubMed Web of Science ®Google Scholar
• Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology 1988: 32(6 Suppl): 27–31
   PubMed Web of Science ®Google Scholar
• Cohen A, Winton L, Luther R, et al. Effect of terazosin on the symptoms of benign prostatic hypertrophy. (Abstr) Clin Pharmacol Ther 1989: 45(2): 183
   Web of Science ®Google Scholar
• Lepor H. Alpha adrenergic antagonists for the treatment of symptomatic BPH. Int J Clin Pharmacol Ther Toxicol 1989: 27(4): 151–5
   PubMed Web of Science ®Google Scholar
• Fabricius PG, Weizert P, Dunzendorfer U, et al. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. Prostate Suppl 1990: 3: 85–93
   PubMedGoogle Scholar
• Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983: 130(2): 275–8
   PubMed Web of Science ®Google Scholar
• Keane WF, Anderson S, Aurell M, et al. Angiotensin converting enzyme inhibitors and progressive renal insufficiency: current experience and future directions. Ann Intern Med 1989: 111(6): 503–16
   PubMed Web of Science ®Google Scholar
• American Society of Hospital Pharmacists. American Hospital Formulary Service drug information 1989. Bethesda, MD: American Society of Hospital Pharmacists, 1989: 850–6
   Google Scholar
• Ibid, pp 919–21
   Google Scholar
• Applegate WB. Hypertension in elderly patients. Ann Intern Med 1989: 110(11): 901–15
   PubMed Web of Science ®Google Scholar
• Ouslander JG. Drug therapy in the elderly. Ann Intern Med 1981: 95(6): 711–22
   PubMed Web of Science ®Google Scholar